{"id":"W2771658548","doi":"10.1093/annonc/mdx764","title":"Adjuvant everolimus in high-risk diffuse large B-cell lymphoma: final results from the PILLAR-2 randomized phase III trial","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":66,"is_retracted":false,"has_abstract":true,"ca_institutions":"Hôpital de l'Enfant-Jésus; Princess Margaret Cancer Centre","funders":"","keywords":"Everolimus; Medicine; Internal medicine; Hazard ratio; Rituximab; Placebo; Common Terminology Criteria for Adverse Events; Clinical endpoint; Oncology; Adverse effect; Randomized controlled trial; Surgery; Gastroenterology; Lymphoma; Confidence interval; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001435778,0.0009514232,0.001869623,0.0001919758,0.0001957434,0.0008818721,0.0006424917,0.0008534197,0.004430426],"category_scores_gemma":[0.001151755,0.0003410454,0.001268748,0.0002128601,0.000452771,0.0005988537,0.0002727801,0.001596376,0.0007154489],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003326144,"about_ca_system_score_gemma":0.0004729845,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002507257,"about_ca_topic_score_gemma":0.0007066022,"domain_scores_codex":[0.9996105,0.0002417564,0.00001924697,0.00005483182,0.00003087848,0.00004282893],"domain_scores_gemma":[0.999543,0.0001330541,0.0001424289,0.00003943713,0.00003038547,0.0001117767],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9429386,0.004311596,0.001819328,0.001680865,0.002948468,0.0001167498,0.00005890081,0.0007748378,0.003371889,0.0002958939,0.003876503,0.03780643],"study_design_scores_gemma":[0.9678688,0.02518733,0.003053412,0.00008829562,0.001167626,0.00008250182,0.00001754275,0.0003975579,0.0003304233,0.0001905282,0.001602654,0.00001327558],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9686202,0.02151951,0.0008157637,0.001282332,0.0004282238,0.001801075,0.0020949,0.0001437945,0.00329423],"genre_scores_gemma":[0.9665189,0.01239216,0.003013969,0.002867656,0.0008289604,0.005111694,0.003992359,0.00004337136,0.005230939],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004430426,"threshold_uncertainty_score":0.01482123,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0702101635286362,"score_gpt":0.3738961772992783,"score_spread":0.3036860137706421,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}